EGFR and non-small cell lung carcinoma: The Food & Drug Administration (FDA) approved erlotinib for NSCLC on 18 November 2004 and has, since 18 October 2016, restricted its use in lung cancer as a first line treatment to metastatic NSCLC with the EGFR mutations listed above.